Bayer and Nimbus Biotechnology in ADME software agreement

Bayer Technology Services, the engineering and applied science spin-off company of Bayer AG, and Leipzig-based Nimbus Biotechnology have signed an exclusive sales and marketing agreement for the prediction ADME-software PK-MAP.

The Bayer Technology Services software will complement Nimbus's portfolio and its well established Transil Early ADME assays.

PK-MAP is a software tool for the assessment of ADME properties of substances in early stages of the drug r&d process. It combines validated mechanistic prediction models with powerful visualisation and selection features which allow a quick overview over the most important ADME and pharmacokinetic parameters for numbers of compounds.

Nimbus Biotechnology Transil Early ADME assays are standard bead-based assays for the rapid and easy determination of the important ADME related parameters lipophilicity/membrane affinity and serum protein binding. These compound properties described as logMA and logKd are preferred input parameters for the prediction software PK-MAP that itself provides good estimates of parameters like the fraction dose absorbed, the unbound fraction in plasma, organ/plasma partition coefficients, and the volume of distribution as demonstrated in various evaluation studies with pharmaceutical companies.

The combination of the Transil Early ADME assays and the software tool PK-MAP leads to a fast, reliable, and therefore highly efficient platform for ADME prediction of new chemical entities and for lead optimisation, according to the companies.

'Late stage failure of a compound is still mostly due to ADME properties. Therefore ADME prediction for a large number of compounds is still highly desirable in modern drug development,' said Dr Alfred Moeps, co-ceo of Nimbus Biotechnology. 'The combination of our Transil Early ADME assays with PK-MAP will overcome this bottleneck and enable our customers to select the most promising compounds at an early stage of discovery.'